About Us
Making a difference, patient by patient
US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs.
Patients are key to everything that we do at US WorldMeds
Vision
We will remain a sustainable, privately held specialty pharmaceutical company.
Mission
We will develop, license, and market meaningful and accessible healthcare products that improve lives and result in a thriving community of patients, employees, and shareholders.
Values
|
QUICK ACCESS TO THE LATEST COMPANY NEWS
Discover the latest news, featured stories, and past news from US WorldMeds
December 14, 2023US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood CancerFirst and only FDA-approved oral maintenance therapy for high-risk neuroblastomaLOUISVILLE, Ky. December 14, 2023 -- USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk neuroblastoma. IWILFIN is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy. Read more |